Brief: Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation

Organon & Co.

27/10/2025 13:15

Organon & Co OGN.N:

ORGANON APPOINTS COMPANY EXECUTIVE JOSEPH MORRISSEY AS INTERIM CEO AND BOARD CHAIR CARRIE COX AS EXECUTIVE CHAIR; ANNOUNCES RESULTS OF AUDIT COMMITTEE INVESTIGATION

ORGANON & CO - APPOINTS JOSEPH MORRISSEY AS INTERIM CEO

ORGANON & CO - KEVIN ALI RESIGNS AS CEO AND BOARD MEMBER

ORGANON: INVESTIGATION FOUND THAT SOME WHOLESALERS IN US WERE ASKED TO BUY MORE NEXPLANON THAN NEEDED AT END OF Q4 2022, Q3 & Q4 2024, Q1, Q2, Q3 2025

ORGANON: INVESTIGATION FOUND NEXPLANON SALES REPRESENTED LESS THAN 1% OF CO'S CONSOLIDATED REVENUE FOR YEAR ENDED DEC 31, 2022 OR DEC 31, 2024

ORGANON & CO: FINDINGS TO DATE DO NOT NECESSITATE A RESTATEMENT OR REVISION TO ANY PREVIOUSLY ISSUED FINANCIAL STATEMENTS

ORGANON & CO: TAKING REMEDIAL ACTIONS TO IMPROVE ITS FINANCIAL CONTROLS AND ADDRESS ANY MATERIAL WEAKNESSES

ORGANON & CO: IN CONNECTION WITH INVESTIGATION, TERMINATED EMPLOYMENT OF HEAD OF U.S. COMMERCIAL & GOVERNMENT AFFAIRS

ORGANON & CO: THERE HAS BEEN NO FINDING THAT CFO WAS AWARE OF IMPROPER WHOLESALER SALES PRACTICES

ORGANON & CO: INITIATING A SEARCH FOR A PERMANENT CEO, INCLUDING BOTH INTERNAL AND EXTERNAL CANDIDATES

ORGANON & CO:  IMPROPER NEXPLANON SALES PRACTICES ENABLED CO TO MEET GUIDANCE AND/OR CERTAIN EXTERNAL REVENUE EXPECTATIONS

Source text: ID:nBw6cK19Ha

Further company coverage: OGN.N